anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Subjects in the control arm will continue with standard diabetes care without getting access to the intervention website. Subjects will also complete questionnaires at baseline and 2, 4, and 6 months post-baseline. Control subjects will be granted access to the health \& wellness website after the study is completed.
Doses of AUC 5-6 of carboplatin in combination with 75 mg/m2 of docetaxel are easily combined, being myelosuppression the most important toxicity. This combination has been studied in metastatic breast cancer as well as in the neoadjuvant setting. The combination of taxanes and platinum salts is increasingly used as neoadjuvant chemotherapy for TNBC. The docetaxel-carboplatin (TCb) regimen is an active and tolerable regimen in metastatic and locally advanced breast cancer, and the efficacy and toxicity characterization in the clinical setting are regaining interest in the era where the role of anthracyclines is controversial in the adjuvant setting. The avoidance of potentially serious long-term toxicities in specific breast cancer subtypes is a real challenge in an attempt to individualize therapies.
Breast cancer is perhaps the most common cancer in women that requires frequent surgical intervention. Nearly 40% of post-operative breast surgery patients experience significant acute post-operative pain, with a pain score above five reflecting inadequacy of conventional pain management. Most of the responses of the human body to post-surgical pain have been proven to be detrimental to the patient's homeostasis and recovery. Moreover, the incidence of chronic postoperative pain in breast surgery patients is as high as 50% and inadequate analgesia is considered as an independent risk factor. Hence, a number of therapeutic measures have been accepted as a part of the "multi-modal" approach to post-operative pain control. Thoracic Paravertebral Block (PVB) is used for pain relief after thoracotomy , and mastectomy. PVB can provide profound, long lasting sensory differentiation. The resulting greater attenuation of surgical stress response may translate into reduced inotropic stimulation of the heart. Additionally, unlike general anesthesia, PVB can provide superior postoperative analgesia, less nausea and vomiting, shorter recovery time; require fewer analgesic, earlier mobilization, and earlier home readiness for discharge. The use of PVB in patients undergoing ambulatory breast surgery has cost-saving potential. There is little systematic research on the efficacy and tolerability of the addition of adjunctive analgesic agent in paravertebral analgesia. The addition of adjunctive analgesics, such as fentanyl and clonidine to local anesthetics has been shown to enhance the quality and duration of sensory neural blockade, and decrease the dose of local anesthetic and supplemental analgesia .

Ketamine is an anaesthetic agent with potent analgesic properties. Its mode of action includes noncompetitive antagonism at N-methyl d-aspartate (NMDA) receptors and a local anaesthetic effect. ketamine has been extensively used through epidural and caudal routes with variable results.It possesses some definite advantages over the conventional local anaesthetic agents as it stimulates cardiovascular system and respiratory system.The advantages of ketamine include a good analgesic effect, cardio vascular stability in a hypotensive state, bronchodilatation in asthmatics, and the absence of awareness. Disadvantages include increased heart rate and blood pressure, emergence phenomenon, laryngospasm and apnea, increases in intracranial and intraocular pressure, and the lack of visceral anesthesia.
This study aims to identify optimal parameters for using Thulium fiber lasers (TFL) in ureteral stone lithotripsy to ensure laser safety and maximize efficacy. Our goal is to improve the outcomes of single-use semi-rigid ureteroscopy for treating stones located in the proximal ureter. A clinically relevant thermal testing device was designed to investigate heating effects during TFL stone fragmentation. The device was utilized to identify safe power thresholds for TFL at various irrigation rates. Three other devices were used to assess varying pulse energy effects on stone fragmentation efficiency, dusting, retropulsion, and depth of tissue vaporization. Comparative experiments in fresh porcine renal units were performed to validate the efficacy and safety of optimal TFL parameters for semi-rigid ureteroscopy in proximal ureteral stone procedures. Our study found that the improved device generated a higher thermal effect. Furthermore, the safe power threshold for laser lithotripsy increased as the irrigation rate was raised. At an irrigation rate of 40 ml/min, it is safe to use an average power of less than 30 watts. Although increasing pulse energy has a progressively lower effect on fragmentation and dust removal efficiency, it did lead to a linear increase in stone displacement and tissue vaporization depth. Thermal testing showed 20 W (53.87 ± 2.67 °C) indicating potential urothelial damage. In our study of laser lithotripsy for proximal ureteral stones, the group treated with 0.3 J pulses had several advantages compared to the 0.8 J group: Fewer large fragments (> 4 mm): 0 vs. 1.67 fragments (1-2.25), p = 0.002, a lower number of collateral tissue injuries: 0.50 (0-1.25) vs. 2.67 (2-4), p = 0.011, and lower stone retropulsion grading: 0.83 (0.75-1) vs. 1.67 (1-2), p = 0.046. There was no significant difference in operating time between the groups (443.33 ± 78.30 s vs. 463.17 ± 75.15 s, p = 0.664). These findings suggest that TFL irradiation generates a greater thermal effect compared to non-irradiated stones. Furthermore, the thermal effect during laser lithotripsy is influenced by both power and irrigation flow rate. Our study suggests that using a power below 15 W with an irrigation flow rate of 20 ml/min is safe. Moreover, a pulse energy of 0.3 J appears to be optimal for achieving the best overall stone fragmentation effect.
The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control. This is an open design study, in which the patients will be aware of the guidance they are receiving via the provided support tool. Study duration of 6 months has been chosen, as a reasonable amount of time to evaluate the tool. Glycaemic control is considered to be the goal of a T2DM disease management plan. In T2DM, long-term goals may not be achieved because participants fail to adhere to their management plan after an initial period of compliance. The study will compare the group receiving the digital disease management tool added to standard care for T2DM to a concurrent control group receiving standard care. Standard of Care cohort: Participants will have standard care with no access to the digital disease management tool. Clinical assessments for this study will be conducted as part of normal, standard care. Participants in the Standard of Care + digital disease management cohort will be taken through their standard T2DM management plan by their HCP (Health Care Provider) and trained in the use of the digital disease management tool. All participants will complete the PRO assessments. This study also aims at helping the health care practitioners and managed care providers to make evidence-based decisions about how to improve patient self-management of their diabetes. Participants diagnosed with T2DM and on one or more non-insulin antihyperglycaemic medications will be offered participation in the study at their point of care. Participants in the Standard of Care cohort will be taken through their T2DM management plan with their HCP per standard care. It is not anticipated that the use of this patient tool will be associated with any increase in risk to participating patients. The study will be performed in accordance with ethical principles that are consistent with International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP), applicable regulatory requirements, and the AZ policy of bioethics.
While the vast majority of Alzheimer's disease (AD) is non-familial, the animal models of AD that are commonly used for studying disease pathogenesis and development of therapy are mostly of a familial form. We aimed to generate a model reminiscent of the etiologies related to the common late-onset Alzheimer's disease (LOAD) sporadic disease that will recapitulate AD/dementia features. Naïve female mice underwent ovariectomy (OVX) to accelerate aging/menopause and were fed a high fat-sugar-salt diet to expose them to factors associated with increased risk of development of dementia/AD. The OVX mice fed a high fat-sugar-salt diet responded by dysregulation of glucose/insulin, lipid, and liver function homeostasis and increased body weight with slightly increased blood pressure. These mice developed AD-brain pathology (amyloid and tangle pathologies), gliosis (increased burden of astrocytes and activated microglia), impaied blood vessel density and neoangiogenesis, with cognitive impairment. Thus, OVX mice fed on a high fat-sugar-salt diet imitate a non-familial sporadic/environmental form of AD/dementia with vascular damage. This model is reminiscent of the etiologies related to the LOAD sporadic disease that represents a high portion of AD patients, with an added value of presenting concomitantly AD and vascular pathology, which is a common condition in dementia. Our model can, thereby, provide a valuable tool for studying disease pathogenesis and for the development of therapeutic approaches.
In Group 1(n=50); continuous infusion of intravenous midazolam (Dormicum, Deva Pharmaceutical, Turkey) at a dose of 0.02 to 0.04 mg/kg/h was started at the beginning of the operation and the dose was adjusted depending on pain level and sedation level using appropriate scales for monitoring throughout the surgical time period. An intravenous bolus dose of midazolam at a dose of 0.015 mg/kg was administered before the start of the surgery. A rescue medication of intravenous bolus dose of remifentanil at a concentration of 5 μg/mL was used every 5 to 10 minutes in doses of 1 to 3 mL if necessary for pain scores greater than 3. The medications were stopped prior to the end of the surgery.
Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Tizanidine occasionally causes liver injury, most often hepatocellular in type. In controlled clinical studies, approximately 5% of patients treated with tizanidine had elevations of liver function tests (ALT/SGPT, AST/SGOT) to greater than 3 times the upper limit of normal (or 2 times if baseline levels were elevated) compared to 0.4% in the control patients. Most cases resolved rapidly upon drug withdrawal with no reported residual problems. In occasional symptomatic cases, nausea, vomiting, anorexia and jaundice have been reported. Based upon postmarketing experience, death associated with liver failure has been a rare occurrence reported in patients treated with tizanidine.

Monitoring of aminotransferase levels is recommended during the first 6 months of treatment (e.g., baseline, 1, 3 and 6 months) and periodically thereafter, based on clinical status. Because of the potential toxic hepatic effect of tizanidine, the drug should ordinarily be avoided or used with extreme caution in patients with impaired hepatic function.
The invention relates to a traditional Chinese medicine medicament for curing insomnia. The prescription of the invention is that wild or spiny jujuba seed 325-975, bupleurum root 190-570, white peony root 190-570, albizia flower 240-720, albizia bark 240-720, batryticated silkworm 150-450, cicada shell 150-450, and rush 15-45 grams. The invention adopts the common methods to prepare miscellaneous medicament types which are capsules, tablets, soft capsules, pelletized granules, oral administration medicaments, pills, dropping pills, externally used immersed medicaments and the like. After the medicament effectiveness test and the clinical test, the medicament is certificated for having the functions of purging the liver of pathogenic fire, relieving depression, and relieving mental stress. The invention is used for curing insomnia which is caused by the depression of liver and the overtaxing of nerves, further the invention cures insomnia and dreamful sleep, mental depression or precipitancy and irascibility, fullness in the chest and hypochondrium or stagnation of the chest dysphagia, and bitter mouth and light-headedness, further the invention cures the symptoms of slightly red tongue border tip, white and slightly yellow tongue coating and wiry pulse essentially. The invention has a relative good curative effect of relieving the fantod and improving the sleeping, and the invention is tested for having a reliable curative effect, thereby the invention can be extensively extended and used.
The present invention relates to vesicles derived from bacteria of the genus  Sphingomonas  and a use thereof. These vesicles were significantly decreased in clinical samples of patients with hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis as compared to normal individuals. Administration of isolated vesicles suppressed secretion of inflammatory mediators by pathogenic vesicles such as  E. coli -derived vesicles. Upon oral administration, the vesicles were distributed in the brain tissue. Vesicles derived from bacteria of the genus  Sphingomonas  are envisioned for use in methods of diagnosis, as well as compositions and methods for treating, hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis. These vesicles are also useful as drug carriers for drug delivery to the brain.
PURPOSE:To obtain the slow-releasing particles suitable for nutrient feed to active vegetable tissue especially among artificial seeds by coating a core body mainly consisting of one or more kinds of monosaccharide, disaccharide or trisaccharide with the film of a film material made of both an ethylene-vinyl acetate copolymer and wax as a main component. CONSTITUTION:The aimed slow-releasing particles are obtained by performing rolling coating or fluidizing coating while spraying the soln. of a film material made of both 10-90wt.% ethylene-vinyl acetate copolymer and 90-10wt.% wax as a main component on a core body mainly consisting of the above- mentioned saccharides. The above-mentioned film material shows permeability extremely large in temp. dependence for low molecular nutrient such as cane sugar and glucose in a state brought into contact with hydrogel. When controlling the blending ratio of the components of the film material and film thickness, nutrient is not permeated at low temp. of 0-4 deg.C. Nutrient of amount correspondent to germination, rootage and growth, etc., of active vegetable tissue is discharged at the temp. of sowing of 20-30 deg.C.
The patient is intubated with Tritube® after the removal of the conventional endotracheal tube (ETT) and Tritube® was advanced until proximal to the carina. Before starting the PDT, measurements with ATP bioluminescence-based method (3M Clean-trace®) were made by taking sample from a sterile PVC (poly vinyl chloride) surface (10 cm2) which is held 50 cm over the operation site. After PDT with Griggs method (Portex), the measurements were repeated by taking sample from surface.
In this clinical trial, 61 patients requiring endodontic retreatments in the posterior teeth were selected. A single visit Endodontic retreatment was done. After biomechanical preparation, Low Level Laser was irradiated to the buccal and lingual mucosa overlying the apices of the target tooth in the experimental group. In the control group patients received placebo laser to eliminate the probable psychological effects of laser. Laser irradiation was done with a single dose of 808 nm wavelength (Whitening Lase II- Laser DMC, Samsung, Korea) with 100 mw power, and dose of 70 J/cm2 for 80 seconds. Pain severity was recorded before the treatment, immediately after the treatment and 4, 8, 12, 24 and 48 hours after the treatment by visual analogue scale (VAS). The pain scores were statistically analyzed by chi-square test between two groups. The effects of different variables on the post-operative pain experience were also studied by means of Logistic regression.
BACKGROUND: Despite advancements in neonatal care, germinal matrix-intraventricular hemorrhage impacts 20% of very preterm infants, exacerbating their neurological prognosis. Understanding its complex, multifactorial pathophysiology and rapid onset remains challenging. This study aims to link specific cord blood biomolecules at birth with post-natal germinal matrix-intraventricular hemorrhage onset.
METHODS: A monocentric, prospective case-control study was conducted at Rouen University Hospital from 2015 to 2020. Premature newborns ( < 30 gestational age) were included and cord blood was sampled in the delivery room. A retrospective matching procedure was held in 2021 to select samples for proteomic and metabolomic analysis of 370 biomolecules.
RESULTS: 26 patients with germinal matrix-intraventricular hemorrhage cases and 60 controls were included. Clinical differences were minimal, except for higher invasive ventilation rates in the germinal matrix-intraventricular hemorrhage group. Germinal matrix-intraventricular hemorrhage newborns exhibited lower phosphatidylcholine levels and elevated levels of four proteins: BOC cell adhesion-associated protein, placental growth factor, Leukocyte-associated immunoglobulin-like receptor 2, and tumor necrosis factor-related apoptosis-inducing ligand receptor 2.
CONCLUSION: This study identifies biomolecules that may be linked to subsequent germinal matrix-intraventricular hemorrhage, suggesting heightened vascular disruption risk as an independent factor. These results need further validation but could serve as early germinal matrix-intraventricular hemorrhage risk biomarkers for future evaluations.
IMPACT: Decrease in certain phosphatidylcholines and increase in four proteins in cord blood at birth may be linked to subsequent germinal matrix-intraventricular hemorrhage in premature newborns. The four proteins are BOC cell adhesion-associated protein, placental growth factor, leukocyte-associated immunoglobulin-like receptor 2, and TNF-related apoptosis-inducing ligand receptor 2. This biological imprint could point toward higher vascular disruption risk as an independent risk factor for this complication and with further validations, could be used for better stratification of premature newborns at birth.
The invention aims at providing a method for treating viruses and cancers by using a cutting enzyme. A current known method for treating viruses and cancers is great in side effect and incapable of realizing targeted elimination. When the cutting enzyme is used for treating viruses and cancers, the incision enzyme design is finished by acquiring sequencing of viruses, and then calculating and positioning an incision enzyme identification sequence. The cutting enzyme enters the human body through tools, such as activated viruses, for conveying the cutting enzyme into the human body, to carry out point location cutting on promoters and others. Further, a patient is healed by means of self repair of cells. The method provided by the invention has the advantages that side effects are less and targeted elimination is achieved.
Powerful local anaesthetic with a short latency time. Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.4%Articaine 1:100000.
A cationic nanoparticle 100 having an inorganic core 120 and at least one outer cationic coating 140 is described. The at least one outer cationic coating 140 substantially covers the inorganic core 120 and has at least one organo-silane. The organo-silane includes: -Si(R1)3 wherein R1 independently at each occurrence is an alkoxy group, a hydroxyl group, a halide, an alkyl group, or hydrogen, and wherein at least one R1 of the three R1s is not an alkyl group. A nanocomplex 500 having a cationic nanoparticle 100 and at least one oligonucleotide 160 attached to the cationic nanoparticle 100 is also described. Methods of making cationic nanoparticles and nanocomplexes are also described. Also described are methods of delivering an oligonucleotide 160 into a cell in-vitro, to a subject in-vivo, and monitoring the delivery of an oligonucleotide.
The use of novel nonionic polymeric thickeners that produce cosmetically useful emulsions of an oil phase and a water phase is described. The thickeners of choice are the urethane dimers of ethoxylated fatty alcohols. These materials were not anticipated to have emulsifying properties. Also, it has been found that the esters of ethoxylated polyols show similar emulsifying behavior, although their uses are limited by their inherent susceptibility towards hydrolysis. Further, many of the emulsions produced with these emulsifiers have a dilatant or shear thickening rheology that is unusual and has unique cosmetic applications. In addition, it is possible to produce high internal phase oil-in-water emulsions, with oil phase concentrations greater than 70%, using these emulsifiers. Finally, many of the emulsions, especially the high internal phase ones, have a characteristic “ring” or vibration that is apparent when their container is tapped. This is a characteristic of so called “microemulsions” that has not been observed in conventional appearing, white (albeit dilatant) emulsions.
PURPOSE:To provide a detergent which dos not harden the skin or hair during use or after drying and gives an excellent use feeling by incorporating an acylglycine salt derived from either a coconut oil fatty acid or a palm kernel oil fatty acid. CONSTITUTION:A coconut oil fatty acid chloride or a palm kernel oil fatty acid chloride is reacted with glycine by the Schotten-Baumann reaction to produce the corresponding acylglycine. This acylglycine is converted into a salt with an alkali metal, an alkaline earth metal, an alkanol amine, etc. A detergent containing this salt in an amount of preferably 5-85wt.% is produced. Incorporation of a polyhydric alcohol such as glycerol or 1,3-butylene glycol into this detergent is effective in further preventing hair hardening and skin drying. The detergent is especially suitable for use as a shampoo, a face detergent, and a body detergent.
FIELD: medicine, pharmacology, pharmacy. SUBSTANCE: invention relates to composition containing diphosphonic acid. Invention proposes a solid pharmaceutical form for administration containing diphosphonic acid or its physiologically compatible salt as active substance. The indicated active substance presents in granulated form being optionally with pharmaceutical adjuvants in the internal phase and the external phase comprises a lubricant as a stearic acid taken in the amount less as about 5% as measured for the total form mass for administration. Invention provides preparing agent that is stable to provide uniform release of an active substance and almost completely for 30 min. EFFECT: improved properties and enhanced effectiveness of composition. 13 cl, 5 tbl, 5 ex